CIBA-GEIGY FEMARA ADVANCED BREAST CANCER APPROVAL RECOMMENDATION BASED ON RESPONSE RATE DATA; CMTE. SPLITS OVER REQUIRING TAMOXIFEN WASHOUT FOR TRIALS
Ciba-Geigy's Femara (letrozole) for advanced breast cancer showed a trend towards superiority over a current therapy: at the 2.5 mg strength, Femara yielded 24% complete plus partial tumor response rate compared with 16% for Bristol-Myers Squibb's Megace (megestrol acetate) in a randomized, double-blind Phase III pivotal trial presented to FDA's Oncologic Drugs Advisory Committee Dec. 16.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth